{"id":87643,"date":"2022-12-12T12:16:00","date_gmt":"2022-12-12T05:16:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022121212160087643"},"modified":"2022-12-12T22:30:03","modified_gmt":"2022-12-12T14:30:03","slug":"%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e8%80%90%e7%ab%8b%e5%85%8br%e4%b8%ad%e5%9b%bd%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e8%bf%9e%e7%bb%ad%e7%ac%ac%e4%ba%94%e5%b9%b4%e5%9c%a8ash%e5%b9%b4%e4%bc%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022121212160087643","title":{"rendered":"\u4e9a\u76db\u533b\u836f\u8010\u7acb\u514b(R)\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u8fde\u7eed\u7b2c\u4e94\u5e74\u5728ASH\u5e74\u4f1a\u8fdb\u884c\u53e3\u5934\u62a5\u544a\uff0c\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u957f\u671f\u7597\u6548\u548c\u5b89\u5168\u6027"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/Ascentage_Pharma_Logo-22.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p><span class=\"legendSpanClass\">\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02<\/span><span class=\"legendSpanClass\">2022\u5e7412\u670812\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5728\u7f8e\u56fd\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5965\u5c14\u826f\u4e3e\u884c\u7684\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\uff0c\u5c31\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b<sup>&reg;<\/sup>\uff09\u7684\u6700\u65b0\u4e2d\u56fd\u4e34\u5e8a\u8fdb\u5c55\u505a\u4e862\u9879\u53e3\u5934\u62a5\u544a\uff0c\u5206\u522b\u4e3a\u8010\u7acb\u514b<sup>&reg;<\/sup>\u7684\u4e2d\u56fd\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u548c\u8be5\u54c1\u79cd\u5728\u4e2d\u56fd\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\uff0c\u6765\u81ea\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u7684\u9ec4\u6653\u519b\u6559\u6388\u4e0e\u6c5f\u5029\u6559\u6388\u4e3a\u5176\u4e3b\u8981\u7814\u7a76\u8005\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u76f8\u5173\u4e34\u5e8a\u8fdb\u5c55\u4eca\u5e74\u5171\u83b73\u9879ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u6c47\u96c6\u4e86\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u53ca\u6700\u65b0\u7684\u836f\u7269\u7814\u53d1\u6570\u636e\uff0c\u5c55\u793a\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u7684\u6700\u9ad8\u5b66\u672f\u6c34\u5e73\u3002\u4f5c\u4e3a\u65e5\u76ca\u6d3b\u8dc3\u5728\u56fd\u9645\u5b66\u672f\u821e\u53f0\u4e0a\u7684\u201c\u4e2d\u56fd\u58f0\u97f3\u201d\uff0c\u4e9a\u76db\u533b\u836f\u5728\u4eca\u5e74\u7684ASH\u5e74\u4f1a\u4e0a\uff0c\u5c06\u901a\u8fc74\u9879\u53e3\u5934\u62a5\u544a\u516c\u5e035\u9879\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u65b0\u6570\u636e\uff0c\u6b64\u5916\uff0c\u516c\u53f8\u591a\u4e2a\u6838\u5fc3\u54c1\u79cd\u76f8\u5173\u8fdb\u5c55\u8fd8\u83b7\u90094\u9879ASH\u5e74\u4f1a\u58c1\u62a5\u5c55\u793a\uff0c\u5176\u4e2d3\u9879\u4e3a\u72ec\u7acb\u7814\u7a76\u8005\u57fa\u4e8e\u771f\u5b9e\u4e16\u754c\u7684\u7814\u7a76\u3002<\/p>\n<p>\u8010\u7acb\u514b<sup>&reg;<\/sup>\u4e2d\u56fd\u4e34\u5e8a\u8fdb\u5c55\u76f8\u5173\u76842\u9879\u53e3\u5934\u62a5\u544a\u5206\u522b\u516c\u5e03\u4e86\u8be5\u54c1\u79cd\u7528\u4e8e\u6cbb\u7597T315I\u7a81\u53d8\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u60a3\u8005\u7684\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u65b0\u6570\u636e\uff0c\u4ee5\u53ca\u4e2d\u56fdCML\u8010\u836f\u60a3\u8005\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\uff08I\u671f\u4e34\u5e8a\u7814\u7a76\uff09\u3002<\/p>\n<p>\u4e24\u9879\u5728\u4e2d\u56fd\u5f00\u5c55\u7684\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u663e\u793a\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728T315I\u7a81\u53d8\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548cCML\u52a0\u901f\u671f\uff08-AP\uff09\u60a3\u8005\u4e2d\u5747\u8868\u73b0\u51fa\u4e86\u4f18\u79c0\u7684\u957f\u671f\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u5728\u5e26\u6709T315I\u7a81\u53d8\u7684CML-CP\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f438\u4e2a\u6708\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08MCyR\uff09\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7ea6\u4e3a83%\u548c59%\uff0c\u5176\u4e2d\u8d85\u8fc780%\u7684\u60a3\u8005\u5728\u672c\u6b21\u516c\u5e03\u6570\u636e\u65f6\u4f9d\u7136\u4fdd\u6301\u4e86\u957f\u671f\u4e14\u7a33\u5b9a\u7684\u6cbb\u7597\u53cd\u5e94\u3002\u5728\u5e26\u6709T315I\u7a81\u53d8\u7684CML-AP\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f420\u4e2a\u6708\uff0cMCyR\u548cMMR\u8fbe\u5230\u4e8652%\u548c48%\u3002\u957f\u671f\u5b89\u5168\u6027\u8868\u73b0\u826f\u597d\uff0c\u548cI\u671f\u7814\u7a76\u6570\u636e\u7c7b\u4f3c\uff0c\u5176\u4e2d\u8840\u7ba1\u6813\u585e\u4e8b\u4ef6\u7684\u53d1\u751f\u7387\u4ec5\u4e3a3%\u3002<\/p>\n<p>BCR-ABL1<sup>T315I<\/sup>\u7a81\u53d8\uff0c\u53c8\u88ab\u79f0\u4e3a\u201c\u95e8\u63a7\u7a81\u53d8\u201d\uff08gatekeeper\uff09\uff0c\u662fCML\u6cbb\u7597\u4e2d\u7684\u4e00\u5927\u6311\u6218\u3002\u5728\u5c55\u73b0\u5176\u6cbb\u7597\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u5353\u8d8a\u7684\u6709\u6548\u6027\u548c\u826f\u597d\u5b89\u5168\u6027\u5916\uff0c\u6b64\u6b21\u53e3\u5934\u62a5\u544a\u7684\u8010\u7acb\u514b<sup>&reg;<\/sup>\u6cbb\u7597\u4e2d\u56fdCML\u8010\u836f\u60a3\u8005\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\u663e\u793a\uff0c\u8be5\u54c1\u79cd\u5728\u5bf9\u7b2c\u4e00\u4ee3\u548c\/\u6216\u7b2c\u4e8c\u4ee3TKI\u8010\u836f\u7684CML-CP\u548cCML-AP\u60a3\u8005\u4e2d\u7684\u7597\u6548\u6df1\u5ea6\u6301\u4e45\u4e14\u5b89\u5168\u6027\u826f\u597d\u3002\u6b64\u5916\uff0c\u8be5\u7814\u7a76\u7684\u591a\u56e0\u7d20\u5206\u6790\u663e\u793a\uff0c\u5728\u57fa\u7ebf\u65f6\u5b58\u5728\u590d\u5408\u7a81\u53d8\u5e76\u672a\u5f71\u54cd\u8010\u7acb\u514b\u7684\u7597\u6548\u3002<\/p>\n<p>\u4f5c\u4e3a\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u4e2d\u56fd\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u957f\u671f\u6cbb\u7597\u7684\u8010\u53d7\u6027\u826f\u597d\uff0c\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\uff08TRAE\uff09\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\u800c\u51cf\u5c11\uff0c\u5305\u62ec\u8840\u6db2\u5b66TRAE\u5728\u5185\u3002\u7279\u522b\u503c\u5f97\u6307\u51fa\u7684\u662f\uff0c\u5728\u56fd\u5916\u4e09\u4ee3TKI\u5448\u73b0\u8f83\u9ad8\u98ce\u9669\u7684\u8840\u7ba1\u5835\u585e\u4e8b\u4ef6\u65b9\u9762\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>50\u4e2a\u6708\u7684\u7d2f\u79ef\u8840\u7ba1\u5835\u585e\u4e8b\u4ef6\u53d1\u751f\u7387\u7ea6\u4e3a7%\uff0c\u660e\u663e\u4f4e\u4e8e\u56fd\u5916\u540c\u7c7b\u4ea7\u54c1\uff08\u7ea6\u4e3a35-40%\uff09\u3002\u53e6\u5916\uff0c\u5728\u4e25\u91cd\u809d\u810f\u6bd2\u6027\u4e8b\u4ef6\u548c\u80f0\u817a\u708e\u4e8b\u4ef6\u65b9\u9762\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u6781\u4f4e\u3002<\/p>\n<p>\u8010\u7acb\u514b<sup>&reg;<\/sup>\u662f\u4e9a\u76db\u533b\u836f\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u6cbb\u7597\u6709\u6548\u836f\u7269\uff0c\u83b7\u56fd\u5bb6\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u9879\u652f\u6301\uff0c\u5728\u5168\u7403\u5c42\u9762\u5177best-in-class\u6f5c\u529b\u3002\u8be5\u54c1\u79cd\u4e8e2021\u5e7411\u6708\u83b7\u6279\u5728\u4e2d\u56fd\u4e0a\u5e02\uff0c\u6253\u7834\u4e86\u4e2d\u56fd\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u957f\u671f\u65e0\u836f\u53ef\u533b\u7684\u56f0\u5883\uff0c\u586b\u8865\u4e86\u56fd\u5185\u4e34\u5e8a\u6cbb\u7597\u3002<\/p>\n<p>\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u526f\u4e3b\u4efb\u6c5f\u5029\u6559\u6388\u8868\u793a\uff1a\u201d\u6b64\u6b21\u6211\u4eec\u53e3\u5934\u62a5\u544a\u7684\u4e24\u9879\u4e34\u5e8a\u7814\u7a76\uff0c\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728T315I\u7a81\u53d8\u7684CML\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6709\u6548\u6027\uff1b\u6b64\u5916\uff0c\u8be5\u54c1\u79cd\u5bf9\u4e8e\u591a\u7ebf\u6cbb\u7597\u5931\u8d25\u3001\u5177\u6709\u590d\u6742\/\u590d\u5408\u8010\u836f\u7a81\u53d8\u7684CML\u60a3\u8005\u4ea6\u6709\u5f88\u5f3a\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff1b\u4e14\u7597\u6548\u6301\u4e45\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u7684\u5b89\u5168\u6027\u826f\u597d\uff0c\u5176\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u5ef6\u957f\u800c\u964d\u4f4e\uff1b\u5728\u8840\u7ba1\u6813\u585e\u4e8b\u4ef6\u3001\u4e25\u91cd\u809d\u6bd2\u6027\u3001\u80f0\u817a\u708e\u7b49\u4e0d\u826f\u53cd\u5e94\u7684\u53d1\u751f\u7387\u65b9\u9762\uff0c\u76f8\u8f83\u56fd\u5916\u540c\u7c7b\u4ea7\u54c1\u5177\u6709\u660e\u663e\u4f18\u52bf\u3002\u201d<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728\u4e2d\u56fd\u7684\u4e34\u5e8a\u7814\u7a76\u8fde\u7eed\u7b2c\u4e94\u5e74\u83b7\u9009ASH\u53e3\u5934\u62a5\u544a\uff0c\u5c55\u73b0\u4e86\u56fd\u9645\u8840\u6db2\u5b66\u5c4a\u5bf9\u8be5\u54c1\u79cd\u7684\u5de8\u5927\u8ba4\u53ef\uff0c\u8fd9\u4ee4\u6211\u4eec\u5907\u53d7\u9f13\u821e\u3002\u6b64\u6b21\u516c\u5e03\u7684\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u8010\u7acb\u514b<sup>&reg;<\/sup>\u6df1\u5ea6\u4e14\u6301\u7eed\u7684\u6709\u6548\u6027\uff0c\u4ee5\u53ca\u826f\u597d\u7684\u957f\u671f\u5b89\u5168\u6027\uff0c\u6211\u4eec\u5bf9\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728\u6162\u7c92\u6cbb\u7597\u9886\u57df\uff0c\u5305\u62ec\u8be5\u54c1\u79cd\u6cbb\u7597\u5bf9\u5176\u5b83TKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\u60a3\u8005\u65b9\u9762\u6240\u62e5\u6709\u7684\u5de8\u5927\u4e34\u5e8a\u6f5c\u529b\u5145\u6ee1\u4fe1\u5fc3\u3002<\/p>\n<p>\u672a\u6765\uff0c\u516c\u53f8\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u8010\u7acb\u514b<sup>&reg;<\/sup>\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\u3002\u540c\u65f6\u79ef\u6781\u6316\u6398\u8010\u7acb\u514b<sup>&reg;<\/sup>\u8fd9\u4e00\u6b3e\u597d\u836f\u7684\u4e34\u5e8a\u6f5c\u529b\uff0c\u63a2\u7d22\u66f4\u591a\u66f4\u5e7f\u7684\u4e34\u5e8a\u9002\u5e94\u8bc1\uff0c\u575a\u6301\u4ee5\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u2019\u4e3a\u4f7f\u547d\uff0c\u4e89\u53d6\u65e9\u65e5\u8ba9\u66f4\u591a\u60a3\u8005\u83b7\u76ca\u3002\u201d<\/p>\n<p>\u8010\u7acb\u514b<sup>&reg;<\/sup>\u57282022 ASH\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u7684\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08APG-2575\u4e0e\u8010\u7acb\u514b<sup>&reg;<\/sup>\u6d77\u5916\u7814\u7a76\u7684\u6458\u8981\u8be6\u7ec6\u4fe1\u606f\u53c2\u89c12022 ASH\u5e74\u4f1a\u671f\u95f4\u53d1\u5e03\u7684\u53e6\u5916\u4e24\u7bc7\u65b0\u95fb\u7a3f\uff09<\/p>\n<p class=\"prntac\"><b>Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation<\/b><\/p>\n<p class=\"prntac\"><b>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/b><b>HQP1351<\/b><b>\uff09\u6cbb\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08<\/b><b>TKI<\/b><b>\uff09\u8010\u836f\u7684<\/b><b>T315I<\/b><b>\u7a81\u53d8\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u548c\u52a0\u901f\u671f\uff08<\/b><b>CML-CP<\/b><b>\u548c<\/b><b>CML-AP<\/b><b>\uff09\u60a3\u8005\u5173\u952e\u6027<\/b><b>II<\/b><b>\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6700\u65b0\u7ed3\u679c<\/b><\/p>\n<ul type=\"disc\">\n<li>\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a<\/li>\n<li>\u6458\u8981\u7f16\u53f7\uff1a#170698<\/li>\n<li>\u5206\u4f1a\u573a\uff1a632. \u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\u8fdb\u5c55\uff1a\u65b0\u578b\u836f\u7269<\/li>\n<li>\u62a5\u544a\u65f6\u95f4\uff1a\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0a\u534810:30\/\u5317\u4eac\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u665a\u4e0a11:30<\/li>\n<li>\u6838\u5fc3\u8981\u70b9\uff1a<\/li>\n<\/ul>\n<p class=\"prnml40\">&#8211; T315I\u7a81\u53d8\u53ef\u4ea7\u751f\u9ad8\u5ea6\u7684\u8010\u836f\u6027\uff0c\u5bf9\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3TKIs\u90fd\u5177\u6709\u9ad8\u5ea6\u8010\u836f\u6027\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u662f\u4e00\u79cd\u65b0\u578b\u7684\u5177\u6709\u53e3\u670d\u6d3b\u6027\u7684\u7b2c\u4e09\u4ee3BCR-ABL1 \u6291\u5236\u5242\uff0c\u5728I\u671f\u7814\u7a76\u826f\u597d\u7ed3\u679c\u7684\u57fa\u7840\u4e0a\uff0c\u5f00\u5c55\u4e86HQP1351-CC-201\u548cHQP1351-CC-202\u4e24\u4e2a\u5173\u952e\u6027\u4e34\u5e8a\u7814\u7a76\uff0c\u7814\u7a76\u6570\u636e\u663e\u793a\u5728\u4f34T315I\u7a81\u53d8\u7684CML-CP\u4ee5\u53caCML-AP\u60a3\u8005\u4e2d\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u8868\u73b0\u51fa\u8f83\u9ad8\u7684\u6709\u6548\u6027\u4ee5\u53ca\u826f\u597d\u7684\u8010\u53d7\u6027\u3002<\/p>\n<p class=\"prnml40\"><b>&#8211; HQP1351-CC-201<\/b><b>\u7814\u7a76\uff08<\/b><b>CML-CP<\/b><b>\uff09<\/b><\/p>\n<p class=\"prnml40\">\u622a\u6b622022\u5e749\u670830\u65e5\uff0c\u5171\u670941\u4f8b\u60a3\u8005\u5165\u7ec4\uff0c\u5176\u4e2d21\u4f8b\uff0851%\uff09\u4e3a\u7537\u6027\uff0c\u4e2d\u4f4d\u5e74\u9f84\uff08\u8303\u56f4\uff09\u4e3a47\uff0822-70\uff09\u5c81\uff0c\u4ece\u8bca\u65ad\u4e3aCML\u5230\u9996\u6b21\u670d\u7528\u5965\u96f7\u5df4\u66ff\u5c3c\u7684\u4e2d\u4f4d\u65f6\u95f4\u4e3a5.3\uff080.6-23.2\uff09\u5e74\uff0c32\u4f8b\uff0878%\uff09\u60a3\u8005\u65e2\u5f80\u63a5\u53d7\u8fc7\u22652\u79cdTKIs\u6cbb\u7597\u3002\u4e2d\u4f4d\u6cbb\u7597\u65f6\u95f4\uff08\u8303\u56f4\uff09\u4e3a38\uff083-41\uff09\u4e2a\u6708\uff0cSanger\u6d4b\u5e8f\u68c0\u6d4b37\u4f8b\uff0890%\uff09\u60a3\u8005\u4f34\u6709\u5355T315I\u7a81\u53d8\uff0c4\u4f8b\uff0810%\uff09\u60a3\u8005\u4f34\u6709T315I\u5408\u5e76\u5176\u4ed6\u7a81\u53d8\u3002<\/p>\n<p class=\"prnml40\">\u521d\u6b65\u7597\u6548\uff1aCML-CP\u60a3\u8005\u7684\u5b8c\u5168\u8840\u6db2\u5b66\u53cd\u5e94\u7387\uff08CHR\uff09\u4e3a100%\uff0831\/31\uff0c\u5176\u4ed610\u540d\u60a3\u8005\u5728\u57fa\u7ebf\u65f6\u5373\u4e3aCHR\uff09\uff0c83%\uff0834\/41\uff09\u7684\u60a3\u8005\u83b7\u5f97MCyR\uff0c73%\uff0830\/41\uff09\u7684\u60a3\u8005\u83b7\u5f97\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08CCyR\uff09\uff0c59%\uff0824\/41\uff09\u7684\u60a3\u8005\u83b7\u5f97MMR\uff0c54%\uff0822\/41\uff09\u7684\u60a3\u8005\u83b7\u5f97\u5206\u5b50\u5b66\u53cd\u5e944.0\uff08MR<sup>4.0<\/sup>\uff09\u300236\u4e2a\u6708\u7684\u7d2f\u79efMCyR\u53cd\u5e94\u7387\u4e3a80%\uff0864%\uff0c90%\uff09\uff0c\u7d2f\u79efCCyR\u53cd\u5e94\u7387\u4e3a71%\uff0854%\uff0c83%\uff09\uff0c\u7d2f\u79efMMR\u53cd\u5e94\u7387\u4e3a59%\uff0842%\uff0c72%\uff09\uff0c\u7d2f\u79efMR<sup>4.0<\/sup>\u53cd\u5e94\u7387\u4e3a51%\uff0835%\uff0c66%\uff09\uff0c\u7d2f\u79efMR<sup>4.5<\/sup>\u53cd\u5e94\u7387\u4e3a51%\uff0835%\uff0c66%\uff09\u300236\u4e2a\u6708\u65f6\u7684\u6301\u7eedMCyR\u53cd\u5e94\u7387\u4e3a80%\uff0861%\uff0c91%\uff09\uff0c\u6301\u7eedCCyR\u53cd\u5e94\u7387\u4e3a81%\uff0860%\uff0c92%\uff09\uff0c\u6301\u7eedMMR\u53cd\u5e94\u7387\u4e3a85%\uff0861%\uff0c95%\uff09\u300236\u4e2a\u6708\u65f6\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\uff08PFS\uff09\u4e3a92%\uff0877%\uff0c97%\uff09\uff0c\u603b\u751f\u5b58\u7387\uff08OS\uff09\u4e3a95%\uff0882%\uff0c99%\uff09\u3002\u5171\u67092\u4f8b\u60a3\u8005\u56e0\u75be\u75c5\u8fdb\u5c55\uff08PD\uff09\u9000\u51fa\uff0c3\u4f8b\u60a3\u8005\u56e0\u6cbb\u7597\u5931\u8d25\u9000\u51fa\uff0c4\u4f8b\u60a3\u8005\u56e0\u4e0d\u8010\u53d7\u9000\u51fa\uff0c3\u4f8b\u60a3\u8005\u64a4\u9500\u77e5\u60c5\uff0c\u9000\u51fa\u7814\u7a76\uff0c2\u4f8b\u60a3\u8005\u56e0\u5176\u4ed6\u539f\u56e0\u9000\u51fa\u3002<\/p>\n<p class=\"prnml40\">\u5b89\u5168\u6027\uff1a\u5e38\u89c1\u7684\u8840\u6db2\u5b66TRAE\uff08\u4efb\u4f55\u7ea7\u522b\uff1b3\/4\u7ea7\uff1bSAEs\uff09\u4f9d\u6b21\u4e3a\u8840\u5c0f\u677f\u51cf\u5c11\u75c7\uff0871%\uff1b49%\uff1b7%\uff09\u3001\u8d2b\u8840\uff0871%\uff1b32%\uff1b2%\uff09\u3001\u767d\u8840\u7403\u51cf\u5c11\u75c7\uff0851%\uff1b15%\uff1b0\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0841%\uff1b22%\uff1b0\uff09\u3002\u5e38\u89c1\u975e\u8840\u6db2\u5b66TRAE\uff08\u4efb\u4f55\u7ea7\u522b\uff1b&nbsp;3-4\u7ea7\uff09\u5305\u62ec\u76ae\u80a4\u8272\u7d20\u6c89\u7740\uff0856%\uff1b0%\uff09\u548c\u808c\u9178\u6fc0\u9176\u5347\u9ad8\uff0856%\uff1b20%\uff09\u3001\u8c37\u4e19\u8f6c\u6c28\u9176\uff08ALT\uff09\u5347\u9ad8\uff0844%\uff1b2%\uff09\u548c\u8c37\u8349\u8f6c\u6c28\u9176\uff08AST\uff09\u5347\u9ad8\uff0837%\uff1b0\uff09\u3002<\/p>\n<p class=\"prnml40\">&#8211; <b>HQP1351-CC-202<\/b><b>\u7814\u7a76\uff08<\/b><b>CML-AP<\/b><b>\uff09<\/b><\/p>\n<p class=\"prnml40\">\u622a\u6b62\u52302022\u5e749\u670830\u65e5\uff0c\u5171\u670923\u540d\u60a3\u8005\u5165\u7ec4\uff0c\u5176\u4e2d18\u540d\uff0878%\uff09\u4e3a\u7537\u6027\uff0c\u4e2d\u4f4d\u5e74\u9f84\uff08\u8303\u56f4\uff09\u4e3a41\uff0821-74\uff09\u5c81\uff0c\u60a3\u8005\u4ece\u8bca\u65ad\u4e3aCML\u5230\u9996\u6b21\u4f7f\u7528\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u7684\u65f6\u95f4\u4e3a5.0\uff080.4-10.2\uff09\u5e74\uff0c19\u4f8b\uff0883%\uff09\u60a3\u8005\u65e2\u5f80\u63a5\u53d7\u22652\u79cdTKIs\u6cbb\u7597\u3002\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u6cbb\u7597\u65f6\u95f4\u4e3a20 \uff081-41\uff09\u4e2a\u6708\uff0cSanger\u6d4b\u5e8f\u68c0\u6d4b19\u4f8b\uff0883%\uff09\u60a3\u8005\u4f34\u6709\u5355T315I\u7a81\u53d8\uff0c4\u4f8b\uff0817%\uff09\u60a3\u8005\u4f34\u6709T315I\u5408\u5e76\u5176\u4ed6\u7a81\u53d8\u3002<\/p>\n<p class=\"prnml40\">\u521d\u6b65\u7597\u6548\uff1aCML-AP\u60a3\u8005\u7684CHR\u4e3a74%\uff0817\/23\uff09\u300236\u4e2a\u6708\u7684\u7d2f\u79efMCyR\u53cd\u5e94\u7387\u4e3a52%\uff0830%\uff0c71%\uff09\uff0c\u7d2f\u79efCCyR\u53cd\u5e94\u7387\u4e3a52%\uff0829%\uff0c71%\uff09\uff0c\u7d2f\u79efMMR\u53cd\u5e94\u7387\u4e3a48%\uff0825%\uff0c68%\uff09\uff0c\u7d2f\u79efMR<sup>4.0<\/sup>\u53cd\u5e94\u7387\u4e3a35%\uff0816%\uff0c55%\uff09\uff0c\u7d2f\u79efMR<sup>4.5<\/sup>\u53cd\u5e94\u7387\u4e3a35%\uff0816%\uff0c55%\uff09\u300236\u4e2a\u6708\u65f6\u7684\u6301\u7eedMCyR\u53cd\u5e94\u7387\u4e3a81%\uff0844%\uff0c95%\uff09\uff0c\u6301\u7eedCCyR\u53cd\u5e94\u7387\u4e3a66%\uff0832%\uff0c86%\uff09\uff0c\u6301\u7eedMMR\u53cd\u5e94\u7387\u4e3a22%\uff084%\uff0c50%\uff09\u300236\u4e2a\u6708\u65f6\u7684PFS\u4e3a62%\uff0838%\uff0c79%\uff09\uff0cOS\u4e3a70%\uff0847%\uff0c84%\uff09\u3002\u5171\u67095\u4f8b\u60a3\u8005\u56e0PD\u9000\u51fa\uff0c2\u4f8b\u60a3\u8005\u56e0\u6cbb\u7597\u5931\u8d25\u9000\u51fa\uff0c4\u4f8b\u60a3\u8005\u56e0\u4e0d\u8010\u53d7\u9000\u51fa\uff0c1\u4f8b\u60a3\u8005\u6b7b\u4ea1\uff0c1\u4f8b\u60a3\u8005\u56e0\u5176\u4ed6\u539f\u56e0\u9000\u51fa\u3002<\/p>\n<p class=\"prnml40\">\u5b89\u5168\u6027\uff1a\u5e38\u89c1\u7684\u8840\u6db2\u5b66TRAE\uff08\u4efb\u4f55\u7ea7\u522b\uff1bG3\/4\uff1bSAEs\uff09\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11\uff0878%\uff1b57%\uff1b17%\uff09\u3001\u8d2b\u8840\uff0870%\uff1b35%\uff1b13%\uff09\u3001\u767d\u8840\u7403\u51cf\u5c11\u75c7\uff0857%\uff1b30%\uff1b0\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u75c7\uff0826%\uff1b26%\uff1b0\uff09\uff1b\u5e38\u89c1\u7684\u975e\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u76ae\u80a4\u8272\u7d20\u6c89\u7740\uff0870%\uff09\u3001\u4f4e\u9499\u8840\u75c7\uff0852%\uff09\u3001\u86cb\u767d\u5c3f\uff0857%\uff09\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff0861%\uff09\u3001\u9ad8\u78f7\u8840\u75c7\uff0848%\uff09\u3001\u9ad8\u5c3f\u9178\u8840\u75c7\uff0826%\uff09\u548c\u5173\u8282\u75db\uff0835%\uff09\uff0c\u5176\u4e2d\u4ee51\/2\u7ea7\u5c45\u591a\u3002<\/p>\n<p class=\"prnml40\">&#8211; \u7ed3\u8bba\uff1a\u5965\u96f7\u5df4\u66ff\u5c3c\u5bf9TKI\u8010\u836f\u4e14\u4f34\u6709T315I\u7a81\u53d8\u7684CML-CP\u548cCML-AP\u60a3\u8005\u5177\u6709\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u8010\u53d7\u6027\uff0c\u7814\u7a76\u7ed3\u679c\u4e0eI\u671f\u7814\u7a76\u4e2dT135I\u7a81\u53d8\u4e9a\u7ec4\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u4e00\u81f4\u3002\u57fa\u4e8e\u8fd9\u4e9b\u5173\u952e\u6027\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7ed3\u679c\uff0c\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u5df2\u4e8e2021\u5e7411\u6708\u9644\u6761\u4ef6\u6279\u51c6\u5965\u96f7\u5df4\u66ff\u5c3c\u4e0a\u5e02\u3002<\/p>\n<p class=\"prntac\"><b>A Five-Year Follow-up on Safety and Efficacy of Olverembatinib <\/b><b>(<\/b><b>HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in <span class=\"xn-location\">China<\/span><\/b><\/p>\n<p class=\"prntac\"><b>\u65b0\u578b\u7b2c\u4e09\u4ee3<\/b><b>BCR-ABL<\/b><b>\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08<\/b><b>TKI<\/b><b>\uff09\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/b><b>HQP1351<\/b><b>\uff09\u5728\u4e2d\u56fd<\/b><b>TKI<\/b><b>\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08<\/b><b>CML<\/b><b>\uff09\u60a3\u8005\u4e2d\u7684<\/b><b>5<\/b><b>\u5e74\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u968f\u8bbf\u6570\u636e<\/b><\/p>\n<ul type=\"disc\">\n<li>\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a<\/li>\n<li>\u6458\u8981\u7f16\u53f7\uff1a#170868<\/li>\n<li>\u5206\u4f1a\u573a\uff1a632. \u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\u8fdb\u5c55\uff1a\u65b0\u578b\u836f\u7269<\/li>\n<li>\u65f6\u95f4\uff1a\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0a\u534810:00\/\u5317\u4eac\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u665a\u4e0a11:00<\/li>\n<li>\u6838\u5fc3\u8981\u70b9\uff1a<\/li>\n<\/ul>\n<p class=\"prnml40\">&#8211; \u8fd9\u9879\u5728\u4e2d\u56fd\u8fdb\u884c\u7684\u5f00\u653e\u6027\u3001\u591a\u4e2d\u5fc3\u7684I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u8bc4\u4f30\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u6210\u5e74CML-CP\u6216CML-AP\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u60275\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\u3002\u7b26\u5408\u6761\u4ef6\u7684\u60a3\u8005\u5305\u62ec\u5bf9\u7b2c\u4e00\u4ee3\u6216\u7b2c\u4e8c\u4ee3TKIs\u8010\u836f\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6216CML-AP\u60a3\u8005\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u7684\u4f7f\u7528\u65b9\u5f0f\u4e3a\u53e3\u670d\u3001\u9694\u65e5\u7ed9\u836f\uff08QOD\uff09\u7684\u65b9\u5f0f\uff0c28\u5929\u4e3a\u4e00\u4e2a\u6cbb\u7597\u5468\u671f\uff0c\u5171\u6709\u8303\u56f4\u4ece1\u81f360mg\u768411\u4e2a\u5242\u91cf\u7ec4\u3002\u4ece2016\u5e7410\u670826\u65e5\u81f32022\u5e749\u670830\u65e5\uff08\u6570\u636e\u622a\u6b62\u65e5\u671f\uff09\uff0c101\u4f8bCML-CP\uff08n=86\uff09\u548cCML-AP\uff08n=15\uff09\u60a3\u8005\u5165\u7ec4\u5e76\u63a5\u53d7\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u3002\u4e2d\u4f4d\u6cbb\u7597\u65f6\u95f4\u4e3a50\u4e2a\u6708\u300271\u4f8b\uff0870%\uff09\u60a3\u8005\u4e3a\u7537\u6027\uff0c\u4e2d\u4f4d\u5e74\u9f84\u4e3a40\u5c81\uff08\u8303\u56f420-64\u5c81\uff09\uff0c\u4ece\u8bca\u65ad\u5230\u9996\u6b21\u63a5\u53d7\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u7684\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u65f6\u95f4\u4e3a6.0\u5e74\uff080.3-15\u5e74\uff09\u300284\u4f8b\uff0883%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u22652\u79cdTKI\u6cbb\u7597\uff0c63\u4f8b\uff0862%\uff09\u60a3\u8005\u643a\u5e26T315I\u7a81\u53d8\u3002\u5728\u57fa\u7ebf\u65f6\uff0c12\u4f8b\uff0812%\uff09\u60a3\u8005\u68c0\u6d4b\u5230\u590d\u5408\u7a81\u53d8\uff0c\u5176\u4e2d8\u4f8b\uff0867%\uff09\u643a\u5e26BCR-ABL1<sup>T315I<\/sup>\u7a81\u53d8\u3002\u5171\u670920\u4f8b\uff0820%\uff09\u60a3\u8005\u67092\uff08n=13\uff09\u6216\u22653\uff08n=7\uff09\u79cd\u7a81\u53d8\u3002\u622a\u81f3\u6570\u636e\u622a\u6b62\u65e5\u671f\uff0c101\u4f8b\u60a3\u8005\u4e2d71\u4f8b\uff0870%\uff09\u7ee7\u7eed\u6cbb\u7597\uff0c30\u4f8b\uff0823\u4f8bCML-CP\u548c7\u4f8bCML-AP\uff09\u56e0\u75be\u75c5\u8fdb\u5c55\uff08PD\uff09\u3001\u4e0d\u8010\u53d7\u6216\u5176\u4ed6\u539f\u56e0\u505c\u6b62\u6cbb\u7597\u3002<\/p>\n<p class=\"prnml40\">&#8211; \u957f\u671f\u7597\u6548\uff1a\u5728\u53ef\u8bc4\u4f30\u7684CML-CP\u60a3\u8005\u4e2d\uff08\u226530mg\u5242\u91cf\u7ec4\uff09\uff0c48\u4e2a\u6708\u7d2f\u8ba1\u53cd\u5e94\u7387MCyR\u4e3a80%\uff0869%\uff0c87%\uff09\uff0cCCyR\u4e3a71%\uff0860%\uff0c80%\uff09\uff0cMMR\u4e3a55%\uff0844%\uff0c65%\uff09\uff0cMR<sup>4.0<\/sup>\u4e3a45%\uff0834%\uff0c55%\uff09\uff0cMR<sup>4.5<\/sup>\u4e3a39%\uff0828%\uff0c49%\uff09\uff1b48\u4e2a\u6708\u6301\u7eed\u53cd\u5e94\u7387MCyR\u4e3a75%\uff0863%\uff0c84%\uff09\uff0cCCyR\u4e3a66%\uff0852%\uff0c77%\uff09\uff0cMMR\u4e3a75%\uff0860%\uff0c86%\uff09. 48\u4e2a\u6708PFS\u4e3a88.6%\uff0879.2%\uff0c93.9%\uff09\uff1b<\/p>\n<p class=\"prnml40\">\u5728\u53ef\u8bc4\u4f30\u7684CML-AP\u60a3\u8005\u4e2d\uff08\u226530mg\u5242\u91cf\u7ec4\uff09\uff0c48\u4e2a\u6708\u7d2f\u8ba1\u53cd\u5e94\u7387MCyR\u4e3a40%\uff0815%\uff0c64%\uff09\uff0cCCyR\u4e3a40%\uff0815%\uff0c64%\uff09,MMR\u4e3a40%\uff0815%\uff0c64%\uff09\uff0cMR<sup>4.0<\/sup>\u4e3a40%\uff0815%\uff0c64%\uff09\uff0cMR<sup>4.5<\/sup>\u4e3a40%\uff0815%\uff0c64%\uff09\u300248\u4e2a\u6708\u6301\u7eed\u53cd\u5e94\u7387MCyR\u4e3a83%\uff0827%\uff0c98%\uff09\uff0cCCyR\u4e3a83%\uff0827%\uff0c98%\uff09\uff0cMMR\u4e3a83%\uff0827%\uff0c98%\uff09\u300248\u4e2a\u6708PFS\u4e3a50%\uff0822.9%\uff0c72.2%\uff09\uff1b<\/p>\n<p class=\"prnml40\">\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u591a\u7a81\u53d8\u7684CML\u60a3\u8005\u4e2d\u4ea6\u8868\u73b0\u51fa\u663e\u8457\u7597\u6548\u3002\u5728\u53ef\u8bc4\u4f30\u7684\u4f34\u6709\u591a\u7a81\u53d8\u7684CML-CP\u60a3\u8005\u4e2d\uff0c48\u4e2a\u6708\u7d2f\u8ba1MCyR\u4e3a64%\uff0cCCyR\u4e3a55%\uff0cMMR\u4e3a58%\uff0cMR<sup>4.0<\/sup>\u4e3a33%\uff0cMR<sup>4.5<\/sup>\u4e3a25%\u3002\u5728\u53ef\u8bc4\u4f30\u7684\u4f34\u6709\u591a\u7a81\u53d8\u7684CML-AP\u60a3\u8005\u4e2d\uff0c48\u4e2a\u6708\u7d2f\u8ba1MCyR\u4e3a60%\uff0cCCyR\u4e3a60%\uff0cMMR\u4e3a60%\uff0cMR<sup>4.0<\/sup>\u4e3a60%\uff0cMR<sup>4.5<\/sup>\u4e3a60% \uff08\u5747\u4e3a\u5728\u63a5\u53d7\u2265&nbsp;30 mg\u5242\u91cf\u60a3\u8005\u4e2d\u89c2\u5bdf\u5230\u7684\u7597\u6548\uff09\u3002<\/p>\n<p class=\"prnml40\">&#8211; 5\u5e74\u5b89\u5168\u6027\u968f\u8bbf\u6570\u636e\uff1a\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u767d\u8840\u7403\u51cf\u5c11\u75c7\u3001\u8d2b\u8840 \u5728\u5185\u7684\u8840\u6db2\u5b66TRAE\u53d1\u751f\u7387\u5448\u4e0b\u964d\u8d8b\u52bf\u30023\/4\u7ea7\u7684\u8840\u5c0f\u677f\u51cf\u5c11\u7684\u53d1\u751f\u7387\u4e0eBCR-ABL1\u662f\u5426\u7a81\u53d8\u3001\u4eceCML\u8bca\u65ad\u5230\u5f00\u59cb\u63a5\u53d7\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u7684\u65f6\u95f4\u95f4\u9694\u76f8\u5173\u3002\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u5305\u62ec\u76ae\u80a4\u8272\u7d20\u6c89\u7740\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\u3001\u86cb\u767d\u5c3f\u5728\u5185\u7684\u975e\u8840\u6db2\u5b66TRAE\u5305\u62ec\u53d1\u751f\u7387\u672a\u89c1\u660e\u663e\u589e\u52a0\u30023\/4\u7ea7\u5fc3\u8840\u7ba1\u4e8b\u4ef6\uff08CVE\uff09\u5305\u62ec\u9ad8\u8840\u538b\uff084%\uff09\u3001\u80ba\u52a8\u8109\u9ad8\u538b\uff081%\uff09\u3001\u4e09\u5c16\u74e3\u529f\u80fd\u4e0d\u5168\uff081%\uff09\u3001\u6025\u6027\u51a0\u72b6\u52a8\u8109\u7efc\u5408\u5f81\uff081%\uff09\u3001\u5fc3\u5f8b\u5931\u5e38\uff081%\uff09\u3001\u51a0\u72b6\u52a8\u8109\u786c\u5316\uff081%\uff09\u3001\u623f\u98a4\uff081%\uff09\u3001\u8111\u6897\u6b7b\uff081%\uff09\u3001\u8154\u9699\u6027\u6897\u6b7b\uff081%\uff09\u3001\u5fc3\u808c\u635f\u4f24\uff081%\uff09\uff0c\u4e5f\u672a\u89c1\u660e\u663e\u589e\u52a0\u8d8b\u52bf\u3002<\/p>\n<p class=\"prnml40\">&#8211; \u7ed3\u8bba\uff1a\u8fd9\u9879\u9996\u6b21\u5728\u4eba\u4f53\u5b9e\u9a8c\u76845\u5e74\u968f\u8bbf\u7ed3\u679c\u663e\u793a\uff0c\u5728TKI\u8010\u836f\u7684CML-CP\u548cCML-AP\u60a3\u8005\u4e2d\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u7684\u6cbb\u7597\u53cd\u5e94\u7387\u968f\u7740\u65f6\u95f4\u63a8\u79fb\u800c\u589e\u52a0\u3002\u5176\u5b89\u5168\u6027\u4e0e\u6b64\u524d\u62a5\u544a\u516c\u5e03\u7684\u6570\u636e\u57fa\u672c\u4e00\u81f4\uff0c\u5927\u591a\u6570TRAE\u53d1\u751f\u7387\u968f\u7740\u65f6\u95f4\u5ef6\u957f\u800c\u4e0b\u964d\u3002<\/p>\n<p><b><u>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67099\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216&nbsp;MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5550\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879\u201c\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730\u201d\u53ca4\u9879\u201c\u521b\u65b0\u836f\u7269\u7814\u53d1\u201d\uff0c\u53e6\u5916\u627f\u62c5\u201c\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb\u201d\u4e13\u98791\u9879\u3002<\/p>\n<p>\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c\u201c\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u201d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p><b><u>About Ascentage Pharma<\/u><\/b><\/p>\n<p>Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On <span class=\"xn-chron\">October 28, 2019<\/span>, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.<\/p>\n<p>Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2\/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 phase 1\/2 clinical trials in the US, <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">China<\/span>. Ascentage Pharma has been designated for multiple Major National R&amp;D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.<\/p>\n<p>Olverembatinib, the company\u2019s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. A New Drug Application (NDA) for HQP1351 has been submitted and subsequently granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) in <span class=\"xn-location\">China<\/span>. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for four of the company\u2019s investigational drug candidates.<\/p>\n<p>Leveraging its robust R&amp;D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales &amp; Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&amp;D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in <span class=\"xn-location\">China<\/span> and around the world for the benefit of more patients.<\/p>\n<p><b><u>\u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n<p><b><u>Forward-Looking Statements<\/u><\/b><\/p>\n<p>The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022022\u5e7412\u670812\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5728\u7f8e\u56fd\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5965\u5c14\u826f\u4e3e\u884c\u7684\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\uff0c\u5c31\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b&reg;\uff09\u7684\u6700\u65b0\u4e2d\u56fd\u4e34\u5e8a\u8fdb\u5c55\u505a\u4e862\u9879\u53e3\u5934\u62a5\u544a\uff0c\u5206\u522b\u4e3a\u8010\u7acb\u514b&reg;\u7684\u4e2d\u56fd\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u548c\u8be5\u54c1\u79cd\u5728\u4e2d\u56fd\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\uff0c\u6765\u81ea\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u7684\u9ec4\u6653\u519b\u6559\u6388\u4e0e\u6c5f\u5029\u6559\u6388\u4e3a\u5176\u4e3b\u8981\u7814\u7a76\u8005\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8010\u7acb\u514b&reg;\u76f8\u5173\u4e34\u5e8a\u8fdb\u5c55\u4eca\u5e74\u5171\u83b73\u9879ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u3002 ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u6c47\u96c6\u4e86\u6700\u524d\u6cbf\u7684\u7814\u7a76\u8fdb\u5c55\u53ca\u6700\u65b0\u7684\u836f\u7269\u7814\u53d1\u6570\u636e\uff0c\u5c55\u793a\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u7684\u6700\u9ad8\u5b66\u672f\u6c34\u5e73\u3002\u4f5c\u4e3a\u65e5\u76ca\u6d3b\u8dc3\u5728\u56fd\u9645\u5b66\u672f\u821e\u53f0\u4e0a\u7684\u201c\u4e2d\u56fd\u58f0\u97f3\u201d\uff0c\u4e9a\u76db\u533b\u836f\u5728\u4eca\u5e74\u7684ASH\u5e74\u4f1a\u4e0a\uff0c\u5c06\u901a\u8fc74\u9879\u53e3\u5934\u62a5\u544a\u516c\u5e035\u9879\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u65b0\u6570\u636e\uff0c\u6b64\u5916\uff0c\u516c\u53f8\u591a\u4e2a\u6838\u5fc3\u54c1\u79cd\u76f8\u5173\u8fdb\u5c55\u8fd8\u83b7\u90094\u9879ASH\u5e74\u4f1a\u58c1\u62a5\u5c55\u793a\uff0c\u5176\u4e2d3\u9879\u4e3a\u72ec\u7acb\u7814\u7a76\u8005\u57fa\u4e8e\u771f\u5b9e\u4e16\u754c\u7684\u7814\u7a76\u3002 \u8010\u7acb\u514b&reg;\u4e2d\u56fd\u4e34\u5e8a\u8fdb\u5c55\u76f8\u5173\u76842\u9879\u53e3\u5934\u62a5\u544a\u5206\u522b\u516c\u5e03\u4e86\u8be5\u54c1\u79cd\u7528\u4e8e\u6cbb\u7597T315I\u7a81\u53d8\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u60a3\u8005\u7684\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u7684\u6700\u65b0\u6570\u636e\uff0c\u4ee5\u53ca\u4e2d\u56fdCML\u8010\u836f\u60a3\u8005\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\uff08I\u671f\u4e34\u5e8a\u7814\u7a76\uff09\u3002 \u4e24\u9879\u5728\u4e2d\u56fd\u5f00\u5c55\u7684\u5173\u952eII\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u663e\u793a\uff0c\u8010\u7acb\u514b&reg;\u5728T315I\u7a81\u53d8\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548cCML\u52a0\u901f\u671f\uff08-AP\uff09\u60a3\u8005\u4e2d\u5747\u8868\u73b0\u51fa\u4e86\u4f18\u79c0\u7684\u957f\u671f\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u5728\u5e26\u6709T315I\u7a81\u53d8\u7684CML-CP\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f438\u4e2a\u6708\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08MCyR\uff09\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7ea6\u4e3a83%\u548c59%\uff0c\u5176\u4e2d\u8d85\u8fc780%\u7684\u60a3\u8005\u5728\u672c\u6b21\u516c\u5e03\u6570\u636e\u65f6\u4f9d\u7136\u4fdd\u6301\u4e86\u957f\u671f\u4e14\u7a33\u5b9a\u7684\u6cbb\u7597\u53cd\u5e94\u3002\u5728\u5e26\u6709T315I\u7a81\u53d8\u7684CML-AP\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f420\u4e2a\u6708\uff0cMCyR\u548cMMR\u8fbe\u5230\u4e8652%\u548c48%\u3002\u957f\u671f\u5b89\u5168\u6027\u8868\u73b0\u826f\u597d\uff0c\u548cI\u671f\u7814\u7a76\u6570\u636e\u7c7b\u4f3c\uff0c\u5176\u4e2d\u8840\u7ba1\u6813\u585e\u4e8b\u4ef6\u7684\u53d1\u751f\u7387\u4ec5\u4e3a3%\u3002 BCR-ABL1T315I\u7a81\u53d8\uff0c\u53c8\u88ab\u79f0\u4e3a\u201c\u95e8\u63a7\u7a81\u53d8\u201d\uff08gatekeeper\uff09\uff0c\u662fCML\u6cbb\u7597\u4e2d\u7684\u4e00\u5927\u6311\u6218\u3002\u5728\u5c55\u73b0\u5176\u6cbb\u7597\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u5353\u8d8a\u7684\u6709\u6548\u6027\u548c\u826f\u597d\u5b89\u5168\u6027\u5916\uff0c\u6b64\u6b21\u53e3\u5934\u62a5\u544a\u7684\u8010\u7acb\u514b&reg;\u6cbb\u7597\u4e2d\u56fdCML\u8010\u836f\u60a3\u8005\u76845\u5e74\u957f\u671f\u968f\u8bbf\u6570\u636e\u663e\u793a\uff0c\u8be5\u54c1\u79cd\u5728\u5bf9\u7b2c\u4e00\u4ee3\u548c\/\u6216\u7b2c\u4e8c\u4ee3TKI\u8010\u836f\u7684CML-CP\u548cCML-AP\u60a3\u8005\u4e2d\u7684\u7597\u6548\u6df1\u5ea6\u6301\u4e45\u4e14\u5b89\u5168\u6027\u826f\u597d\u3002\u6b64\u5916\uff0c\u8be5\u7814\u7a76\u7684\u591a\u56e0\u7d20\u5206\u6790\u663e\u793a\uff0c\u5728\u57fa\u7ebf\u65f6\u5b58\u5728\u590d\u5408\u7a81\u53d8\u5e76\u672a\u5f71\u54cd\u8010\u7acb\u514b\u7684\u7597\u6548\u3002 \u4f5c\u4e3a\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u4e2d\u56fd\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b&reg;\u957f\u671f\u6cbb\u7597\u7684\u8010\u53d7\u6027\u826f\u597d\uff0c\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\uff08TRAE\uff09\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\u800c\u51cf\u5c11\uff0c\u5305\u62ec\u8840\u6db2\u5b66TRAE\u5728\u5185\u3002\u7279\u522b\u503c\u5f97\u6307\u51fa\u7684\u662f\uff0c\u5728\u56fd\u5916\u4e09\u4ee3TKI\u5448\u73b0\u8f83\u9ad8\u98ce\u9669\u7684\u8840\u7ba1\u5835\u585e\u4e8b\u4ef6\u65b9\u9762\uff0c\u8010\u7acb\u514b&reg;50\u4e2a\u6708\u7684\u7d2f\u79ef\u8840\u7ba1\u5835\u585e\u4e8b\u4ef6\u53d1\u751f\u7387\u7ea6\u4e3a7%\uff0c\u660e\u663e\u4f4e\u4e8e\u56fd\u5916\u540c\u7c7b\u4ea7\u54c1\uff08\u7ea6\u4e3a35-40%\uff09\u3002\u53e6\u5916\uff0c\u5728\u4e25\u91cd\u809d\u810f\u6bd2\u6027\u4e8b\u4ef6\u548c\u80f0\u817a\u708e\u4e8b\u4ef6\u65b9\u9762\uff0c\u8010\u7acb\u514b&reg;\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u6781\u4f4e\u3002 \u8010\u7acb\u514b&reg;\u662f\u4e9a\u76db\u533b\u836f\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u6cbb\u7597\u6709\u6548\u836f\u7269\uff0c\u83b7\u56fd\u5bb6\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u9879\u652f\u6301\uff0c\u5728\u5168\u7403\u5c42\u9762\u5177best-in-class\u6f5c\u529b\u3002\u8be5\u54c1\u79cd\u4e8e2021\u5e7411\u6708\u83b7\u6279\u5728\u4e2d\u56fd\u4e0a\u5e02\uff0c\u6253\u7834\u4e86\u4e2d\u56fd\u4f34T315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u957f\u671f\u65e0\u836f\u53ef\u533b\u7684\u56f0\u5883\uff0c\u586b\u8865\u4e86\u56fd\u5185\u4e34\u5e8a\u6cbb\u7597\u3002 \u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u526f\u4e3b\u4efb\u6c5f\u5029\u6559\u6388\u8868\u793a\uff1a\u201d\u6b64\u6b21\u6211\u4eec\u53e3\u5934\u62a5\u544a\u7684\u4e24\u9879\u4e34\u5e8a\u7814\u7a76\uff0c\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u8010\u7acb\u514b&reg;\u5728T315I\u7a81\u53d8\u7684CML\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6709\u6548\u6027\uff1b\u6b64\u5916\uff0c\u8be5\u54c1\u79cd\u5bf9\u4e8e\u591a\u7ebf\u6cbb\u7597\u5931\u8d25\u3001\u5177\u6709\u590d\u6742\/\u590d\u5408\u8010\u836f\u7a81\u53d8\u7684CML\u60a3\u8005\u4ea6\u6709\u5f88\u5f3a\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff1b\u4e14\u7597\u6548\u6301\u4e45\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8010\u7acb\u514b&reg;\u7684\u5b89\u5168\u6027\u826f\u597d\uff0c\u5176\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u5ef6\u957f\u800c\u964d\u4f4e\uff1b\u5728\u8840\u7ba1\u6813\u585e\u4e8b\u4ef6\u3001\u4e25\u91cd\u809d\u6bd2\u6027\u3001\u80f0\u817a\u708e\u7b49\u4e0d\u826f\u53cd\u5e94\u7684\u53d1\u751f\u7387\u65b9\u9762\uff0c\u76f8\u8f83\u56fd\u5916\u540c\u7c7b\u4ea7\u54c1\u5177\u6709\u660e\u663e\u4f18\u52bf\u3002\u201d \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u8010\u7acb\u514b&reg;\u5728\u4e2d\u56fd\u7684\u4e34\u5e8a\u7814\u7a76\u8fde\u7eed\u7b2c\u4e94\u5e74\u83b7\u9009ASH\u53e3\u5934\u62a5\u544a\uff0c\u5c55\u73b0\u4e86\u56fd\u9645\u8840\u6db2\u5b66\u5c4a\u5bf9\u8be5\u54c1\u79cd\u7684\u5de8\u5927\u8ba4\u53ef\uff0c\u8fd9\u4ee4\u6211\u4eec\u5907\u53d7\u9f13\u821e\u3002\u6b64\u6b21\u516c\u5e03\u7684\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u8010\u7acb\u514b&reg;\u6df1\u5ea6\u4e14\u6301\u7eed\u7684\u6709\u6548\u6027\uff0c\u4ee5\u53ca\u826f\u597d\u7684\u957f\u671f\u5b89\u5168\u6027\uff0c\u6211\u4eec\u5bf9\u8010\u7acb\u514b&reg;\u5728\u6162\u7c92\u6cbb\u7597\u9886\u57df\uff0c\u5305\u62ec\u8be5\u54c1\u79cd\u6cbb\u7597\u5bf9\u5176\u5b83TKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\u60a3\u8005\u65b9\u9762\u6240\u62e5\u6709\u7684\u5de8\u5927\u4e34\u5e8a\u6f5c\u529b\u5145\u6ee1\u4fe1\u5fc3\u3002 \u672a\u6765\uff0c\u516c\u53f8\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u8010\u7acb\u514b&reg;\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\u3002\u540c\u65f6\u79ef\u6781\u6316\u6398\u8010\u7acb\u514b&reg;\u8fd9\u4e00\u6b3e\u597d\u836f\u7684\u4e34\u5e8a\u6f5c\u529b\uff0c\u63a2\u7d22\u66f4\u591a\u66f4\u5e7f\u7684\u4e34\u5e8a\u9002\u5e94\u8bc1\uff0c\u575a\u6301\u4ee5\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u2019\u4e3a\u4f7f\u547d\uff0c\u4e89\u53d6\u65e9\u65e5\u8ba9\u66f4\u591a\u60a3\u8005\u83b7\u76ca\u3002\u201d \u8010\u7acb\u514b&reg;\u57282022 ASH\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u7684\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08APG-2575\u4e0e\u8010\u7acb\u514b&reg;\u6d77\u5916\u7814\u7a76\u7684\u6458\u8981\u8be6\u7ec6\u4fe1\u606f\u53c2\u89c12022 ASH\u5e74\u4f1a\u671f\u95f4\u53d1\u5e03\u7684\u53e6\u5916\u4e24\u7bc7\u65b0\u95fb\u7a3f\uff09 Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u8010\u836f\u7684T315I\u7a81\u53d8\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u548c\u52a0\u901f\u671f\uff08CML-CP\u548cCML-AP\uff09\u60a3\u8005\u5173\u952e\u6027II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6700\u65b0\u7ed3\u679c \u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a \u6458\u8981\u7f16\u53f7\uff1a#170698 \u5206\u4f1a\u573a\uff1a632. \u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\u8fdb\u5c55\uff1a\u65b0\u578b\u836f\u7269 \u62a5\u544a\u65f6\u95f4\uff1a\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0a\u534810:30\/\u5317\u4eac\u65f6\u95f42022\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u516d\uff0c\u665a\u4e0a11:30 \u6838\u5fc3\u8981\u70b9\uff1a &#8211; T315I\u7a81\u53d8\u53ef\u4ea7\u751f\u9ad8\u5ea6\u7684\u8010\u836f\u6027\uff0c\u5bf9\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3TKIs\u90fd\u5177\u6709\u9ad8\u5ea6\u8010\u836f\u6027\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u662f\u4e00\u79cd\u65b0\u578b\u7684\u5177\u6709\u53e3\u670d\u6d3b\u6027\u7684\u7b2c\u4e09\u4ee3BCR-ABL1 \u6291\u5236\u5242\uff0c\u5728I\u671f\u7814\u7a76\u826f\u597d\u7ed3\u679c\u7684\u57fa\u7840\u4e0a\uff0c\u5f00\u5c55\u4e86HQP1351-CC-201\u548cHQP1351-CC-202\u4e24\u4e2a\u5173\u952e\u6027\u4e34\u5e8a\u7814\u7a76\uff0c\u7814\u7a76\u6570\u636e\u663e\u793a\u5728\u4f34T315I\u7a81\u53d8\u7684CML-CP\u4ee5\u53caCML-AP\u60a3\u8005\u4e2d\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u8868\u73b0\u51fa\u8f83\u9ad8\u7684\u6709\u6548\u6027\u4ee5\u53ca\u826f\u597d\u7684\u8010\u53d7\u6027\u3002&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2022121212160087643\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-87643","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=87643"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87643\/revisions"}],"predecessor-version":[{"id":87645,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87643\/revisions\/87645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=87643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=87643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=87643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}